Telix Acquires Radioisotope Maker ITM in Deal Worth Up to $2.35B After FDA Setback
- Telix Pharmaceuticals (Australia) agreed to acquire privately held ITM Isotope Technologies Munich (Germany) for about $1.65 billion upfront, largely in Telix shares plus assumed ITM debt, with up to $700 million more in milestones for a potential $2.35 billion total.
- The deal follows the FDA's surprise rejection of ITM's lead drug ITM-11, a GEP-NET radiopharmaceutical meant to rival Novartis's Lutathera, over manufacturing issues at a third-party facility, not safety or efficacy concerns.
- ITM also brings a profitable, commercial-scale isotope production and supply business, strengthening Telix's control over its radiopharmaceutical isotope supply chain.
- Post-close, Telix shareholders will hold about 76.3% of the combined firm, with ITM shareholders holding about 23.7%.
- Combined pro forma 2026 revenue is projected above $1.3 billion, with positive operating earnings expected from 2027.
This is a supply-chain acquisition wearing a pipeline-expansion label. Telix just watched ITM's lead asset get rejected over third-party manufacturing — not efficacy — so buying the isotope producer outright is the cleanest way to internalize that risk rather than keep depending on external CDMOs. Expect Telix to lean hard on ITM's commercial-scale production capacity to de-bottleneck its own growing radiotherapeutic franchise. The structure tells the real story: roughly $1.65B mostly in stock plus assumed debt, with $700M gated behind milestones, is classic risk-sharing for an asset whose flagship product just got an unexpected FDA no. Telix isn't paying cash for certainty it doesn't have yet. Strategically, this vaults Telix into direct, vertically integrated competition with Novartis's Lutathera franchise, and signals radiopharma is entering a consolidation phase where isotope supply, not just molecules, is the scarce asset worth owning.
Radiopharma companies merge after one receives surprise FDA rejection ↗